Ardelyx, Inc. (ARDX) stock
ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3059% below fair value
$3.09−0.03 (-0.96%)
Close on Nov 13, 2026Market cap $769.99MP/E –Yield –
Ardelyx EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Ardelyx's EPS for the twelve months ending Jun 30, 2026 was -$0.22. For fiscal 2025 it was -$0.26. The highest annual figure on record is -$0.17 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.26 | – |
| FY2024 | Dec 31, 2024 | -$0.17 | – |
| FY2023 | Dec 31, 2023 | -$0.30 | – |
| FY2022 | Dec 31, 2022 | -$0.42 | – |
| FY2021 | Dec 31, 2021 | -$1.52 | – |
| FY2020 | Dec 31, 2020 | -$1.05 | – |
| FY2019 | Dec 31, 2019 | -$1.47 | – |
| FY2018 | Dec 31, 2018 | -$1.62 | – |
| FY2017 | Dec 31, 2017 | -$1.36 | – |
| FY2016 | Dec 31, 2016 | -$2.80 | – |
| FY2015 | Dec 31, 2015 | -$1.29 | – |
| FY2014 | Dec 31, 2014 | -$0.31 | – |
| FY2013 | Dec 31, 2013 | -$5.82 | – |
| FY2012 | Dec 31, 2012 | -$11.32 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.07 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.15 | – |
| Q4 FY2025 | Dec 31, 2025 | $0.00 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0.00 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.08 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.17 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.02 | – |
| Q3 FY2024 | Sep 30, 2024 | $0.00 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | -$0.07 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.11 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.12 | -300.0% |
| Q3 FY2023 | Sep 30, 2023 | $0.03 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.08 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.13 | – |
| Q4 FY2022 | Dec 31, 2022 | $0.06 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.14 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.19 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.21 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.31 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.42 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.45 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.34 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.32 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.20 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.28 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.25 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.27 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.37 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.41 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.42 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.45 | -314.3% |
| Q3 FY2018 | Sep 30, 2018 | -$0.39 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.42 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.36 | – |
| Q4 FY2017 | Dec 31, 2017 | $0.21 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.44 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.54 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.59 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.66 | – |
| Q3 FY2016 | Sep 30, 2016 | -$0.65 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?